Multiple System Atrophy Market to Grow with a CAGR of 3.11% through 2030

Rising Prevalence of Neurodegenerative Disorders is expected to drive the Global Multiple System Atrophy Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Multiple System Atrophy- Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Multiple System Atrophy Market stood at USD 149.73 Million in 2024 and is anticipated to grow with a CAGR of 3.11% through 2030. The increasing prevalence of neurodegenerative disorders is a key driver for the global Multiple System Atrophy (MSA) market. As the global population ages, the incidence of neurodegenerative diseases, including MSA, is rising, leading to higher demand for both diagnostic solutions and effective treatments. This trend is particularly pronounced in regions with aging populations, such as North America and Europe, where there is an expanding need for specialized care and management options. The growing burden of MSA is prompting healthcare systems to invest in advanced diagnostic technologies, such as MRI, PET scans, and biomarker-based blood tests, which are crucial for early detection and accurate diagnosis. Early diagnosis is essential for improving patient outcomes, contributing to an expanding market for solutions aimed at addressing the disease in its initial stages.

Furthermore, the rising number of MSA cases is driving increased research and development, with pharmaceutical companies focusing on developing innovative treatments, including targeted therapies, gene therapies, and precision medicine. This growing research activity is accelerating the development and approval of new therapies. As awareness of neurodegenerative diseases increases, there is a heightened demand for specialized care, clinical trials, and healthcare resources, which continues to propel the growth of the MSA market. Additionally, the rising prevalence of MSA is attracting more government and institutional support for research funding and clinical programs, ensuring ongoing progress in both diagnostics and treatment options.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " Global Multiple System Atrophy Market”

Global Multiple System Atrophy Market is segmented into diagnosis, age, end user, regional distribution, and company.

Based on Age, geriatric emerged as the dominating segment in the global market for Multiple System Atrophy in 2024. MSA primarily affects individuals over the age of 50, with the majority of cases diagnosed in those aged 60 and above. As neurodegenerative diseases like MSA predominantly impact older adults, the geriatric demographic represents the largest group of patients affected by the condition. With increasing global life expectancy, more people are living longer, raising the number of individuals at risk for age-related neurodegenerative disorders, including MSA. This extended lifespan leads to a higher prevalence of MSA in the elderly population. As neurodegenerative diseases tend to worsen over time, the risk of developing conditions such as MSA and Parkinson's disease rises with age, further emphasizing the dominance of the geriatric segment in the market.

Older adults often require specialized care due to the complexities of managing multiple health conditions simultaneously. This creates a demand for advanced diagnostic tools and targeted treatments tailored to the needs of elderly patients, driving the market for MSA-related healthcare solutions. Additionally, with the growing elderly population, healthcare systems and research institutions are prioritizing the development of diagnostics and therapies for aging individuals, contributing to the expansion of the MSA market. The geriatric population's dominant presence in the market is a result of the higher incidence of MSA among older adults, the increasing risk of neurodegenerative diseases with age, and the rising demand for specialized care and treatments for the elderly.

Based on Region, the Asia Pacific region is expected to be fastest growing region during the forecast period in global Multiple System Atrophy market. The Asia Pacific region, especially countries like Japan, China, and South Korea, is experiencing rapid growth in its elderly population. As aging is a key risk factor for neurodegenerative diseases such as MSA, the demand for both diagnostic and therapeutic solutions is increasing in these markets. Many nations in Asia Pacific are significantly investing in healthcare infrastructure, including the adoption of advanced diagnostic tools like MRI and PET scans, which are crucial for accurate MSA diagnosis. This has improved access to healthcare services for MSA patients.

As awareness of neurodegenerative diseases, including MSA, grows and diagnostic capabilities advance, more cases are being identified. Early detection is driving demand for targeted therapies and specialized care across the region. The rising investment in healthcare research, supported by both public and private sectors, is accelerating the development of new treatments for MSA and other related disorders in Asia Pacific. The region is increasingly becoming a hub for clinical trials, further contributing to market expansion. Rising healthcare expenditure in emerging markets like China and India is enhancing access to quality care and treatment options, with expanded health insurance coverage enabling more patients to seek treatment for conditions such as MSA. Additionally, Asia Pacific's large and diverse patient population, along with lower operational costs, makes it a key region for clinical trials and research on neurodegenerative diseases, driving further investment in new therapies and diagnostic technologies. This trend is propelling continued market growth in the region.

Major companies operating in Global Multiple System Atrophy Market are:

• Biohaven Ltd.
• Theravance Biopharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Alterity Therapeutics
• AstraZeneca plc.
• Biogen
• Merck & Co., Inc.
• Neuropore Therapies, Inc.
• WaveBreak Therapeutics
• Newron Pharmaceuticals SPA

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The global Multiple System Atrophy (MSA) market is evolving rapidly, with technological innovation playing a pivotal role in its growth. As the demand for personalized and precision medicine intensifies, MSA treatment paradigms are shifting toward highly tailored approaches that address individual patient needs. Advances in artificial intelligence (AI) and machine learning are enhancing diagnostic accuracy, enabling earlier detection and more effective monitoring of disease progression. Furthermore, the increasing collaboration between biotech companies and research institutions is accelerating the development of next-generation therapies, including gene editing and cellular therapies. This convergence of technology, research, and patient-centered care is positioning the MSA market for transformative growth, unlocking new possibilities for improved patient outcomes”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Multiple System Atrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, Others), By Age (Pediatric, Adults, Geriatric), By End User (Hospitals, Ambulatory Surgical Centers, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Multiple System Atrophy Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Multiple System Atrophy Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com